Horizon Discovery (Group)

https://www.horizondiscovery.com

Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. The Company's proprietary technology, GENESIS, is the world's most precise genome editing technology. Using GENESIS, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell-line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes. Horizon has harnessed GENESIS to create over 400 X-MAN cell lines, the world's first source of genetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients. These 'patients-in-a-test-tube' are being used by academic and industry leaders to identify the effect of individual genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments. This enables the design of shorter, more focused, and less expensive clinical trials, ultimately providing the tools to identify the 'right drugs' for the 'right patients' based upon the unique genetic mutations that define their disease. In addition to the X-MAN cell lines, Horizon provides GENESIS and X-MAN derived products and services, with industrial application in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomic-based clinical research platforms. *

	Start	2007-06-01 established
	Group	PerkinElmer (Group)
	Today	PerkinElmer (Group)
	Successor	PerkinElmer (Group)
	Industry	drug discovery
	Person	Pizzie, Terry (Astrea Bioseparations 202107– CEO before Horizon Discovery Pacific Biosciences + Genetix + Biacore + ABI)

	City	CB25 9TL Waterbeach, Cambridgeshire
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	GBP
	Annual sales	20,156,000 (revenue, consolidated (2015) 2015-12-31)
	Profit	-9,883,000 (2015-12-31)
	Cash	25,067,000 (2015-12-31)

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for PerkinElmer (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)